US OptionsDetailed Quotes
HCM240517C20000
- 2.00
- 0.000.00%
15min DelayTrading May 10 09:30 ET
0.00High0.00Low
0.00Open2.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover2065.86%IV18.28%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry2.00Time Value100Contract SizeAmericanOptions Type0.5534Delta0.1172Gamma9.30Leverage Ratio-28.6204Theta0.0000Rho5.15Eff Leverage0.0006Vega
Hutchmed (China) Stock Discussion
Sign in to post a comment
2
$HUTCHMED(00013.HK$ 👀 tight pivot
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
15
Shares of $联拓生物(LIAN.US$ — which focuses on “developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries” — are soaring on Tuesday. Earlier this morning, the company announced a key agreement with $Bristol-Myers Squibb(BMY.US$ regarding exclusive rights to a cardiovascular therapeutic. Subsequently, LIAN stock is up more than 130% as of this writing.
According to the ac...
According to the ac...
6
$Hutchmed (China)(HCM.US$ no attention here and it keeps releasing good pr and goes up steadily
$Hutchmed (China)(HCM.US$ keep an eye on this
4
Gainers:
In reaction to earnings/guidance:
• $Karuna Therapeutics(KRTX.US$ +42.6% (also reports topline results from its Phase3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT), $monday.com(MNDY.US$ +15.1%, $W&T Offshore(WTI.US$ +6.7%, $HF Sinclair(DINO.US$ +5.3%, $Viatris(VTRS.US$ +4.3%, $Kosmos Energy(KOS.US$ + 3.2%, $Holly Energy(HEP.US$ +3.2%, $Barrick Gold(GOLD.US$ +2.9%,...
In reaction to earnings/guidance:
• $Karuna Therapeutics(KRTX.US$ +42.6% (also reports topline results from its Phase3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT), $monday.com(MNDY.US$ +15.1%, $W&T Offshore(WTI.US$ +6.7%, $HF Sinclair(DINO.US$ +5.3%, $Viatris(VTRS.US$ +4.3%, $Kosmos Energy(KOS.US$ + 3.2%, $Holly Energy(HEP.US$ +3.2%, $Barrick Gold(GOLD.US$ +2.9%,...
16
2
$Moderna(MRNA.US$
This was a sale that was planned ahead of time by the CEO of Moderna. It was not a random sale on the open market. But a few things to take away from this SEC filing. The transaction was planned to happen after the first half of the year during quad witching where repositioning volume is at its peak. This was a very large transaction and the CEO was only disposing shares of Moderna. There were a couple conversions of stock options but thery we...
This was a sale that was planned ahead of time by the CEO of Moderna. It was not a random sale on the open market. But a few things to take away from this SEC filing. The transaction was planned to happen after the first half of the year during quad witching where repositioning volume is at its peak. This was a very large transaction and the CEO was only disposing shares of Moderna. There were a couple conversions of stock options but thery we...
8
2
No comment yet
Prasadssvga : Do you think is ready?
Momentum TraderOP Prasadssvga: Already Bo from pivot. Don’t chase high!